- Home
- QTWO vs PRCT Comparison
QTWO vs PRCT Comparison
Compare QTWO & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTWO
- PRCT
- Stock Information
- Founded
- QTWO 2004
- PRCT 2009
- Country
- QTWO United States
- PRCT United States
- Employees
- QTWO N/A
- PRCT N/A
- Industry
- QTWO Computer Software: Prepackaged Software
- PRCT Medical Specialities
- Sector
- QTWO Technology
- PRCT Health Care
- Exchange
- QTWO Nasdaq
- PRCT Nasdaq
- Market Cap
- QTWO 5.6B
- PRCT 4.7B
- IPO Year
- QTWO 2014
- PRCT 2021
- Fundamental
- Price
- QTWO $87.74
- PRCT $62.25
- Analyst Decision
- QTWO Buy
- PRCT Strong Buy
- Analyst Count
- QTWO 17
- PRCT 7
- Target Price
- QTWO $99.53
- PRCT $97.86
- AVG Volume (30 Days)
- QTWO 702.8K
- PRCT 764.2K
- Earning Date
- QTWO 02-12-2025
- PRCT 02-25-2025
- Dividend Yield
- QTWO N/A
- PRCT N/A
- EPS Growth
- QTWO N/A
- PRCT N/A
- EPS
- QTWO N/A
- PRCT N/A
- Revenue
- QTWO $696,464,000.00
- PRCT $199,843,000.00
- Revenue This Year
- QTWO $13.08
- PRCT $67.07
- Revenue Next Year
- QTWO $11.92
- PRCT $40.64
- P/E Ratio
- QTWO N/A
- PRCT N/A
- Revenue Growth
- QTWO 11.50
- PRCT 71.71
- 52 Week Low
- QTWO $44.74
- PRCT $45.20
- 52 Week High
- QTWO $112.82
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- QTWO 35.67
- PRCT 29.56
- Support Level
- QTWO $89.66
- PRCT $64.04
- Resistance Level
- QTWO $95.37
- PRCT $68.38
- Average True Range (ATR)
- QTWO 3.78
- PRCT 3.30
- MACD
- QTWO -0.30
- PRCT -0.15
- Stochastic Oscillator
- QTWO 2.15
- PRCT 1.14
About QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.